MLYS Just Got Rejected at the $30 Ceiling— Now $28 Decides Whether the Pre-FDA Base Cracks

Mineralys is one drug and one date away from its whole story. This morning the chart is saying the stock can't yet hold its highest level in weeks— and the line that decides whether the run survives is $28.

Mineralys Therapeutics traded to $29.945, then rolled over. By the time the data snapshot was taken at 9:20 a.m. ET, MLYS sat at $28.20, down 3.75% on the session, pressing its lows on volume heavy enough to turn over roughly 2.9% of the float. Zone-out trips like this are ordinary for a small-cap biotech; what makes this one a contest is where it happened and what comes next.

The stock is one molecule. Lorundrostat, an aldosterone-synthase inhibitor for hard-to-control blood pressure, is the entire investment case, and the FDA has set a target decision date of December 22, 2026. That is roughly fourteen weeks away. Everything between now and then is positioning for a binary release— and today, the positioning went the wrong way at an overhead wall.

The August run just met its wall

Put the move in sequence. MLYS bottomed at $22.30 over the trailing 52 weeks, spent the middle of the year rebuilding, and spent the last month climbing— about 8% over twenty sessions— toward a ceiling the chart has now failed to clear. That shelf sits around $29.40 to $30, a level the stock reached and was turned away from first thing Friday morning. The high print of $29.945 was the test. The close of the rejection is the rollover.

This is the pattern to name: a stock pushing up a month into a multiweek ceiling, spiking through it intraday, then getting slapped back below the old range high. The buyers who chased the breakout above the prior ceiling are momentarily under water. Whether they get trapped depends entirely on what the next move does with $28.17— the low of this session— which sits just above the summer base the stock escaped.

Participation is what separates a real rejection from a shrugged-off slip. The turnover rate near 2.9% and the 6% intraday amplitude tell you options are also pricing chaos: implied volatility sits near 78%, a level that says the market is treating the December FDA decision as close to a coin flip rather than a foregone conclusion.

The pressure isn't the news— it's the calendar

There is no company headline driving this morning's fade. The catalysts are the kind that hang over the chart rather than hit it. The FDA's PDUFA date on December 22 is the destination. Around it sit ordinary-sounding facts that matter a lot for a pre-revenue company: the second-quarter adjusted loss widened to $2.85 a share versus the roughly $2.60 analysts expected, and the balance sheet still holds about $661 million in cash as of June 30. Add in disclosed CFO and CCO selling under 10b5-1 plans, and you get a stock carrying both shareholder-seller overhang and a hard nearing deadline.

A cash-rich single-asset biotech, fourteen weeks from a binary FDA date, failing at a key ceiling on the back of insider-sale pressure: that is the setup in one sentence. The angle is not that the drug succeeded or failed— nobody knows yet. The angle is that the chart is now asking holders and would-be buyers to pay up for a risk that is increasingly being discounted at the ceiling.

Everything runs through $28

Here is the line, and it is earned, not rounded. Today's low is $28.17. Just beneath it sits the summer base near the high-$20s that the August breakout began from. That is the shelf with memory: the zone where the recent move was built and where the money that pushed the stock up eight percent now lives.

Hold $28 and the pre-approval base stays in place. The rejection becomes a normal shakeout ahead of a date the options market is already pricing as unpredictable, and the ceiling near $30 remains the level to reclaim for the run toward December.

Lose $28 on a close— let a session finish below the shelf with participation still high— and the August breakout is exposed. The chart does not offer much structure on the way down until the summer base, then the $22.30 low that marked the year's capitulation. That is the air pocket traders are paying the 78% volatility premium to protect against.

Scenario	Trigger	Path	Invalidation	Horizon
Base holds	$28 shelf defends, then reclaim of ~$30	Shakeout ahead of PDUFA; ceiling becomes breakout for December run	Close back under $27.9	Session-to-December
Breakout fails	Sustained close below $28	Air pocket toward summer base, then the $22.30 low	No reclaim of $28 within a session or two	Days to weeks

The verdict is binary and resolvable by the clock. Hold $28 and this is a biotech base doing what bases do for fourteen more weeks— built on a real cash cushion and a real catalyst, with the market openly admitting it cannot price the outcome. Lose $28 and the recent breakout, the one that drew in this month's buyers, is on the wrong side of the trade. The market, as of this morning, is leaning on the wrong side. The close will show whether $28 finally gets defended.

As of 9:20 a.m. ET. Price action and levels are derived from live market data and can shift within the session. This is an analysis of chart structure, not a recommendation to buy or sell.